Acurx Pharmaceuticals (ACXP) Net Cash Flow (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Net Cash Flow for 7 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 1.31% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.6 million (up 1647.62% YoY), and the FY2025 full-year result was $3.8 million, up 202.17% from the prior year.
• Net Cash Flow fell to $1.4 million in Q2 2026 per ACXP's latest filing, from $1.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $1.7 million in Q1 2026 and bottomed at -$2.6 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$530074.5 across 5 years, with a median of -$1.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 587.33% in 2024, then soared 180.22% in 2025.
• Over 5 years, Net Cash Flow stood at -$1.5 million in 2022, then surged by 128.21% to $421859.0 in 2023, then plunged by 587.33% to -$2.1 million in 2024, then soared by 180.22% to $1.6 million in 2025, then slipped by 15.02% to $1.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $1.4 million, $1.7 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.